Halozyme finishes investigation of the production of recalled Hylenex

08/31/2010 | Los Angeles Times (tiered subscription model)

Halozyme Therapeutics has finished investigating how glass particles ended up in some vials of Hylenex, a fluid-absorption drug recalled by manufacturing partner Baxter International in May. The investigation found that the drug and the glass vial were incompatible. The companies are preparing to present their corrective action and relaunch strategy to the FDA.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ